Roche
YTD Revenues: CHF 39.4 billion (+5%)
Comments: For the first nine months, Pharmaceutical sales were CHF 30.6 billion for the first nine months, up 5% driven mainly by Ocrevus (CHF 500 million), Tecentriq (CHF 355 million) and Perjeta (CHF 1.6 billion, up 17%). Ocrevu was recently launched for relapsing and primary progressive multiple sclerosis and Tecentriq saw an uptick in metastatic bladder cancer and in metastatic non-small cell lung cancer (NSCLC).MabThera/Rituxan sales were CHF 5.6 billion, up 2%. Herceptin sales were CHF 5.2 billion, up 2%. Avastin sales were down 2% to CHF 5.0 billion. Xolair sales were up 17% to CHF 1.3 billion. Lucentis sales were CHF 1.1 billion, up 4%. Activase/TNKase sales were CHF 920 million, up 14%.